Xeris unveils long-range strategy; targets ~$750M revenue by 2030

Xeris Biopharma Holdings, Inc.

Reaffirms 2025 total revenue guidance of $260-$275M and commitment to adjusted EBITDA positivity.
Expects total revenue of ~$750M by 2030, led by Recorlev growth.
Anticipates Recorlev annual net revenue of ~$1B in 2035; XP-8121 peak net revenue $1-3B.
Cites Recorlev revenue acceleration as inflection point to self-fund near- and long-term growth.
Hosts first Analyst and Investor Day on June 3, 2025, in New York City.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.